Wave Life Sciences Ltd. (WVE): Gregory L. Verdine , director of Wave Life Sciences Ltd. sold 52,000 shares on Jun 15, 2016. The Insider selling transaction was reported by the company on Jun 17, 2016 to the Securities and Exchange Commission. The shares were sold at $16.70 per share for a total value of $868,400.00 , the company said in a SEC Form 4 Filing.
Wave Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. The Company uses synthetic chemistry drug development platform to design develop and commercialize a pipeline of nucleic acid therapeutic candidates. It develops nucleic acid therapeutics that are capable of targeting diseases in a range of organ systems and tissues. Its advanced therapeutic programs are in Huntington’s disease Duchenne muscular dystrophy (DMD) and inflammatory bowel disease (IBD). In Huntington’s disease the Company has programs targeting HTT SNP-1 and HTT SNP-2; in DMD it is targeting Exon 51 and in IBD it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD in which it is focused on an additional DMD target Activin Receptor type IIb. Its subsidiaries include WAVE Life Sciences USA Inc. and WAVE Life Sciences (Japan).